TABLE 1.
T1D patient description
| Patient code | Patient symbol* | Age (years) | Sex | Diabetes duration (years) | RAPA treatment (days) | [RAPA]† (ng/ml) | C-peptide (ng/ml) |
A1C (%) |
EIR (units · kg−1 · day−1) |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRE | RAPA | PRE | RAPA | PRE | RAPA | |||||||
| Hsr-066-ITA-rp06 | ○ | 39 | M | 32 | 109 | 9 | 0.70 | 0.77 | 9.5 | 8.9 | 0.63 | 0.53 |
| Hsr-065-ITA-rp05 | • | 40 | F | 11 | 153 | 24 | 0.15 | 0.28 | 8.7 | 8.7 | 0.89 | 0.79 |
| Hsr-069-ITA7-rp07 |  |
31 | M | 26 | 32 | 21 | 0.02 | 0.02 | 9.1 | nt | 0.63 | 0.51 |
| Hsr-063-ITA-rp03 | ▴ | 48 | F | 37 | 130 | 5 | 0.03 | 0.16 | 6.2 | 6.6 | 0.73 | 0.71 |
| Hsr-064-ITA-rp04 | □ | 33 | F | 21 | 109 | 12 | 0.02 | 0.02 | 8.9 | 9.5 | 0.65 | 0.57 |
| Hsr-ATG-ITA-rp02 | ▪ | 32 | M | 7 | 97 | 5 | 0.01 | 0.01 | 8.7 | 8.7 | 0.74 | 0.42 |
| Mean | 39.2 | 22.3 | 105 | 13 | ||||||||
| Range | 31–48 | 7–37 | 32–153 | 5–24 | ||||||||
*
Symbols recalled throughout the manuscript.
†
Circulating plasma rapamycin concentration. EIR, exogenous insulin requirements; PRE, sample before rapamycin treatment; RAPA, sample during rapamycin treatment.